VASOXYL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 28m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOXYL is an injectable small-molecule vasopressor approved in 1949 by GSK. The exact mechanism of action and indications are not publicly detailed in available data, but the product is classified as a legacy injectable therapeutic. This drug represents a mature, historically significant pharmaceutical asset with limited contemporary clinical development.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial team likely focused on managed transition and cost containment rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VASOXYL represents a mature, legacy asset with zero open job postings, reflecting minimal hiring and career progression opportunity. Assignment to this product is typically a maintenance or transition role rather than a growth platform.
Product ManagerRegulatory Affairs Specialist
Worked on VASOXYL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.